SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chirodoc who wrote (3007)7/19/1998 7:55:00 PM
From: Prospector  Read Replies (1) of 5402
 
Mr Chirodoc

Answers to your questions as per Dr Drees

1. Flousol had slight allergic reactions in clinical trail patients, which went away when mild steroids were given to the few patients affected. The new formulation has a tighter bond in the emulsion, because the new surfactant is also fluoronated to improve emulsion stability so that he finished emulsion does not have to be frozen, as did fluosol.

2. Time table for Phase 1 (19990 , Phase 2 (2000) Phase 3 (2001).

3. The dosage will vary with the usage,i.e. angioplasty (400 ml ), transfusion (500 ml x 4) etc.

4. We will branch out to the 150 areas we know about, and more.

5. Most likely side affects of PHER-02 is a slight allergic reaction and it is not dose dependant.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News